An Open-Label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma or NK/T-Cell Lymphoma After Failure of Conventional Chemotherapy.

Trial Profile

An Open-Label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma or NK/T-Cell Lymphoma After Failure of Conventional Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Bortezomib (Primary) ; Panobinostat (Primary)
  • Indications Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Trial design presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Five patients have been enrolled to date.
    • 14 Nov 2009 Actual initiation date (1 Nov 2009) added as reported by ClinicalTrials.gov.
    • 14 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top